Westpac Banking Corp’s Nektar Therapeutics NKTR Stock Holding History

Westpac Banking Corp’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-701	Closed	-$191K	–	889
2019 Q3	$191K	Hold	701	–	–	﹤0.01%	856
2019 Q2	$374K	Hold	701	–	–	0.01%	690
2019 Q1	$353K	Hold	701	–	–	0.01%	688
2018 Q4	$346K	Hold	701	–	–	0.01%	760
2018 Q3	$641K	Hold	701	–	–	0.01%	622
2018 Q2	$513K	Buy	+701	New	+$808K	0.01%	637

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Westpac Banking Corp's NKTR Position: Q4 2019 in Review

Westpac Banking Corp sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 701 shares — an estimated $191K sold.

Westpac Banking Corp first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $641K in Q3 2018. 280 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

Westpac Banking Corp reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
Westpac Banking Corp sold 701 Nektar Therapeutics shares in Q4 2019, an estimated $191K.
Westpac Banking Corp first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
Westpac Banking Corp's Nektar Therapeutics position peaked at $641K in Q3 2018.
280 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Westpac Banking Corp's 13F filing for Q4 2019, filed 11 Feb 2020.